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Abstract
Background The clearance of cytochrome P450 (CYP) 3A
substrates is reported to be reduced with lower age,
inflammation and obesity. As it is unknown what the
overall influence is of these factors in the case of obese
adolescents vs. morbidly obese adults, we studied covari-
ates influencing the clearance of the CYP3A substrate
midazolam in a combined analysis of data from obese
adolescents and morbidly obese adults.
Methods Data from 19 obese adolescents [102.7 kg
(62–149.5 kg)] and 20 morbidly obese adults [144 kg
(112–186 kg)] receiving intravenous midazolam were
analysed, using population pharmacokinetic modelling
(NONMEM 7.2). In the covariate analysis, the influence of
study group, age, total body weight (TBW), developmental
weight (WTfor age and length) and excess body weight
(WTexcess = TBW - WTfor age and length) was evaluated.
Results The population mean midazolam clearance was
significantly higher in obese adolescents than in mor-
bidly obese adults [0.71 (7%) vs. 0.44 (11%) L/min;
p\ 0.01]. Moreover, clearance in obese adolescents
increased with TBW (p\ 0.01), which seemed mainly
explained by WTexcess, and for which a so-called ‘ex-
cess weight’ model scaling WTfor age and length to the
power of 0.75 and a separate function for WTexcess was
proposed.
Discussion We hypothesise that higher midazolam
clearance in obese adolescents is explained by less
obesity-induced suppression of CYP3A activity, while
the increase with WTexcess is explained by increased
liver blood flow. The approach characterising the
influence of obesity in the paediatric population we
propose here may be of value for use in future studies in
obese adolescents.
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Key Points
Midazolam clearance is higher in obese adolescents
compared with morbidly obese adults, which shows
that it is not justified to assume that clearance is
lower in obese adolescents compared with obese
adults.
In obese adolescents, midazolam clearance increased
mainly with WTexcess (=TBW - WTfor age and length)
for which a novel modelling approach was proposed
with 0.75 allometric scaling on the basis of
WTfor age and length and a separate function for
WTexcess.
With this so-called excess weight model, we propose
a novel approach characterizing the influence of
obesity in the paediatric population, providing
guidance on data analysis for future paediatric
obesity studies.
1 Introduction
Cytochrome P450 (CYP) 3A is an important enzyme sys-
tem, responsible for the primary metabolism of 25% of all
clinically used drugs [1]. This enzyme system is known to
vary with age, inflammation and obesity [2–6]. Its activity
is reported to be low at birth and reaches adult values in the
first years of life [6, 7], after which the size of the liver and/
or liver flow determines the increase in CYP3A clearance.
Recently, a study on midazolam, a well-known probe for
CYP3A [8, 9], showed that this system is also highly
influenced by inflammation and sepsis in children [4]. In
obesity, which may be seen as a chronic state of inflam-
mation, reduced CYP3A protein expression or CYP3A
activity has been reported in in-vitro and obese mice
studies [10–13]. Moreover, in humans, reduced oral
clearance of midazolam in obese subjects compared with
non-obese subjects was reported for various CYP3A sub-
strates [3], even though no difference in midazolam
clearance in obese vs. non-obese individuals was found
[14]. Yet, a 1.7-fold increase in midazolam clearance in
patients 1 year after bariatric surgery was reported, indi-
cating a reduced CYP3A hepatic activity in these morbidly
obese individuals before their weight loss surgery [15–17].
An important question is how the CYP3A system is
influenced by both age and obesity, particularly in view of
the increasing prevalence of obesity in both adults and
children [18]. Allometric scaling on the basis of body
weight with an exponent of 0.75 is often used to describe
the finding that clearance in children is generally lower
than in adults [19–21]. In particular, there is agreement on
this approach for adolescents. The US Food and Drug
Administration already proposed in 2012 that allometric
scaling based on adult data, without the use of a dedicated
pharmacokinetic study, is a reasonable approach for scaling
to adolescents [22]. More recently, there is further evidence
to use allometric scaling in (non-obese) children above the
age of 5 years [23]. However, given the increase in body
weights of both adults and children observed presently as a
result of the obesity epidemic [18], this approach that uses
body weight as a proxy for size, may be questionable in
obese individuals.
A combined (covariate) analysis of data from both obese
adolescents and obese adults may give an appropriate
answer to this question. As total body weight (TBW) in the
obese individual consists of the sum of body weight related
to development (WTfor age and length) and excess body
weight related to obesity (WTexcess), in such an analysis,
potentially a different influence of these types of weight
may be expected on a specific pharmacokinetic parameter
[24]. While for clearance body weight related to size
(WTfor age and length), 0.75 allometric scaling may be
applied [23], WTexcess may or may not have an impact. For
instance for some drugs, adult clearance is known to vary
with obesity while this is not the case for others [3].
Moreover, even when obese adolescents have the same
body weight as obese adults, the (patho)physiologic chan-
ges associated with obesity, for instance inflammation
[25, 26], exist for a shorter time, thereby potentially
altering their influence.
In this article, we study the clearance of the CYP3A
substrate midazolam in obese adolescents and morbidly
obese adults in a combined analysis. Moreover, we explore
a model that can be used to consider obesity in the pae-
diatric population, given the obesity epidemic we are cur-
rently facing.
2 Methods
2.1 Patients
Model building was based on data from 19 adolescents [27]
and 20 adults [14]. The study in obese adolescents was
conducted at the Children’s National Health System
(Washington DC, USA) [Institutional Review Board Pro-
tocol No. 4718] and considered three overweight [body
mass index (BMI) for age 85th to B95th percentile] and 16
obese (BMI for age C95th percentile) adolescents between
12 and 18 years of age undergoing general surgery (such as
orthopaedic surgery, tonsillectomy, bariatric surgery) [27].
The study in the morbidly obese adults (BMI[40 kg/m2)
undergoing bariatric surgery was conducted at St. Antonius
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Hospital (Nieuwegein, The Netherlands) [VCMO
NL35861.100.11, EudraCT 2011-003293-93] [14]. Before
participation, patients of both studies provided written
informed consent. Both studies were conducted in accor-
dance with the principles of the Declaration of Helsinki.
Patient characteristics of both studies are summarised in
Table 1.
2.2 Study Procedure for Obese Adolescents
Obese adolescents received a single intravenous bolus dose
of 2 or 3 mg a few minutes before they were taken to the
operating room. Blood samples were collected at T = 0,
(5), 15 and 30 min and 1, 2, 4, 6 and occasionally at 8 h.
More information on the study procedure can be found in
the published paper [27].
2.3 Study Procedure for Morbidly Obese Adults
Morbidly obese adults received 7.5 mg of midazolam
orally followed by a 5 mg intravenous bolus dose of
midazolam at induction of anaesthesia (159 ± 67 min after
the oral dose). Blood samples were collected at T = 0, 5,
15, 30, 45, 55, 65, 75, 90, 120 and 150 min after the oral
dose and T = 5, 15, 30, 90, 120, 150, 180, 210, 270, 330,
390 and 510 min after the intravenous dose. More infor-
mation on the study procedure can be found in the pub-
lished paper [14].
2.4 Population Pharmacokinetic Analysis
and Internal Model Validation
All data were analysed using non-linear mixed-effects
modelling with NONMEM version 7.2 (ICON Develop-
ment Solutions, Hanover, MD, USA) [28]. Pirana (2.9.1)
[29], R (3.0.1) [30], Xpose (4.5.0) [29] and Psn (3.6.2)
[29] were used to evaluate and visualise the data. Of the
129 midazolam plasma samples of obese adolescents, no
observations were below the limit of quantification
(0.5 ng/mL) [27]. Of the total of 434 samples from the
morbidly obese adults, 33 values (7.6%) were below the
limit of detection and removed from the analysis. Mida-
zolam plasma concentrations between the limit of quan-
tification (\0.8 ng/mL) and limit of detection (\0.3 ng/
mL) [14] were kept in the analysis (n = 9). The first-order
conditional estimation method with interaction was used
for model development. Discrimination between different
models was guided by the likelihood ratio test comparing
the objective function value (OFV, i.e. -2 log likelihood)
between nested models. A p value of\0.05, representing
a decrease of 3.84 in OFV for one degree of freedom, was
considered statistically significant. In addition, goodness-
of-fit plots (observed vs. individual predicted concentra-
tions, observed vs. population predicted concentrations,
conditional weighted residuals vs. time after dose, and
conditional weighted residuals vs. population predicted
concentrations plots) upon midazolam in morbidly obese
adults and obese adolescents were used for diagnostic
purposes. Furthermore, precision of parameter estimates,
the correlation matrix and visual improvement in the
individual plots were used to evaluate the model. Phar-
macokinetic models incorporating two or three compart-
ments for midazolam were tested. The oral data of the
morbidly obese adults were described by optimization of a
five transit absorption compartment model, in which the
transit compartment rate constant (Ktr) was equalised to
the oral absorption rate constant (Ka) [14]. Inter-individ-
ual variability was assumed to follow a log normal dis-
tribution. Residual variability was tested using
proportional, additive, or combined proportional and
Table 1 Demographic
parameters of 19 obese
adolescents [27] and 20
morbidly obese adults [14]
Parameter Overweight and obese adolescents (n = 19) Morbidly obese adults (n = 20)
Female/male 13/6 12/8
Overweight/obese 3/16
Age (years) 15.9 ± 1.6 (12.5–18.9) 43.6 ± 7.6 (26–57)
Body weight (kg) 102.7 ± 24.9 (62–149.8) 144.4 ± 21.7 (112.3–186.3)
BMI (kg/m2) 36.1 ± 8.1 (24.8–55) 47.1 ± 6.5 (39.9–67.6)
BMI z score 2.2 ± 0.4 (1.5–2.7)
LBW (kg) [31] 57.3 ± 11.1 (39.8–74.4) 71.5 ± 11.9 (53.4–94.9)
WTfor age and length (kg) 57.8 ± 7.6 (43–72.3)
WTexcess (kg) 44.8 ± 21.9 (14.6–92)
%WTexcess (%) 77.4 ± 37.1 (30.8–159.1)
Values are expressed as mean ± standard deviation (range) unless specified otherwise
BMI body mass index, LBW lean body weight, WTexcess excess body weight, WTfor age and length develop-
mental weight
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additive error models. For internal model evaluation, a
stratified bootstrap resampling method with 1000 repli-
cates and normalised prediction distribution errors with
1000 simulations were used.
2.5 Covariate Analysis
Covariates were study population, TBW, BMI, lean body
weight according to the equation of Janmahasatian et al.
[31], age, race and sex. Covariates were plotted indepen-
dently against the eta (g) estimates of the pharmacokinetic
parameters to visualise potential relations. Continuous
covariates were tested using linear and power equations
(Eqs. 1, 2):
Pi ¼ Pp  ð1þ Y  ðCOV  COVmedianÞÞ; ð1Þ
Pi ¼ Pp  ðCOV=COVmedianÞX ð2Þ
where Pi and Pp represent individual and population
parameter estimates, respectively, COV represents the
covariate, COVmedian represents the median value of the
covariate for the population, Y represents the linear rela-
tionship between the population pharmacokinetic parame-
ter and the change in covariate value for a linear function,
and X represents the exponent for a power function. The
categorical covariates sex and study population were
examined by estimating a separate parameter for each
category of the covariate.
Potential covariates were entered into the model one at a
time and statistically tested by the likelihood ratio test. In
addition, if applicable, a reduction in inter-individual
variability (omega) of the parameter was evaluated upon
inclusion of the covariate on the parameter. Further, trends
in the random effects of the parameter vs. the covariate
involved were observed. After forward inclusion
(p\ 0.01), a backward exclusion procedure was applied to
justify the inclusion of a covariate (p\ 0.001). The choice
of the covariate model was further evaluated as discussed
in Sect. 2.4.
2.6 Excess Weight Covariate Model
To further analyse the influence of excess weight on the
pharmacokinetics of midazolam for the obese adolescents,
an excess weight covariate model was tested for the
parameters for which TBW proved a covariate, as descri-
bed under covariate analysis. In this model, the TBW of
obese adolescents was considered to be composed of two
parts: developmental weight (WTfor age and length) and
excess body weight (WTexcess) [27]. For each individual
adolescent of the study, WTfor age and length, WTexcess and
relative WTexcess (%WTexcess) were calculated using
Eqs. 3, 4 and 5 respectively:
WTfor age and length ¼ BMIwithout overweight  length2; ð3Þ
WTexcess ¼ TBW WTfor age and length; ð4Þ
%WTexcess ¼ ðWTexcess=WTfor age and lengthÞ  100%; ð5Þ
in which BMIwithout overweight is the BMI derived from the
BMI-for-age Centers for Disease Control and Prevention
growth chart (sex specific) at a BMI z score of 0 together
with the age of the patient [32] and TBW is the total body
weight of the patient.
First, WTfor age and length, WTexcess and %WTexcess were
plotted independently against the eta estimate for clearance
to visualise the relation. Then, the impact of WTfor age
and length and WTexcess on clearance in adolescents was
evaluated using Eqs. 6 and 7:
CLnonobese adolescent ¼ CLnonobese adults
 ðWTfor age and length=70Þ0:75; ð6Þ
CLðobeseÞ adolescent ¼ CLnonobese adolescent þ ðY WTexcessÞ;
ð7Þ
in which CLnon-obese adolescent represents the clearance
estimate of adolescents without overweight with CLnon-
obese adults representing the population clearance of non-
obese adults [14], WTfor age and length representing devel-
opmental weight and 0.75 being the scaling factor that was
previously proposed by the Food and Drug Administration
for scaling clearance in (non-obese) adolescents [22].
CL(obese) adolescent represents the individual clearance esti-
mates of (obese) adolescents and Y represents the linear
relationship between clearance estimates of adolescents
without overweight (CLnon-obese adolescent) and the change in
clearance with WTexcess.
3 Results
3.1 Patients and Data
The pharmacokinetic analysis was based on 530 observa-
tions from 19 obese adolescents [27] and 20 morbidly
obese adults [14]. A summary of all patient characteristics
is presented in Table 1.
3.2 Population Pharmacokinetic Model
and Internal Model Evaluation
Based on the data, a two-compartment model was identi-
fied, in which study population proved a significant
covariate for clearance. Figure 1 shows that midazolam
clearance in obese adolescents was significantly higher
compared with morbidly obese adults (DOFV -8.0;
p\ 0.01). Moreover, in obese adolescents, midazolam
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clearance increased significantly with TBW (DOFV -10.6;
p\ 0.01). As a third covariate, the peripheral volume of
distribution of morbidly obese adults increased signifi-
cantly with TBW in a non-linear manner (DOFV -10.9;
p\ 0.001). All three covariates fulfilled the criteria of the
backward analysis (p\ 0.001). No significant trend was
found for TBW and clearance in the morbidly obese adults,
nor for TBW and peripheral volume of distribution of
midazolam in the obese adolescents (p[ 0.05). No other
covariates (age, BMI, lean body weight [31], race and sex)
had a significant influence on any of the pharmacokinetic
parameters (p[ 0.05). The model parameters of the base
model without covariates and the final covariate model are
summarised in Table 2. Observed vs. individual predicted
concentrations and observed vs. population predicted
concentrations for midazolam in morbidly obese adults and
obese adolescents are shown in Fig. 2. The final model was
validated by 1000 bootstrap runs, which were successful in
93% of the runs and confirmed the parameter values
(Table 2). In addition, a normalised prediction distribution
error analysis was performed showing no trends or bias for
the two populations (Electronic Supplementary Material).
To further analyse the influence of excess weight in
obese adolescents, in Fig. 3, clearance in obese adolescents
is plotted against developmental weight (WTfor age and
length) and excess body weight (WTexcess and %WTexcess).
Figure 3 shows no obvious trend between WTfor age and
length and midazolam clearance in obese adolescents, while
a positive trend was observed between WTexcess or
%WTexcess and midazolam clearance (DOFV -8.5 and
-5.7; p\ 0.01 and p\ 0.05, respectively). To capture the
potential contribution of these different weight measures in
obese adolescents, we propose an excess weight covariate
model (Eqs. 6 and 7, Sect. 2), in which WTfor age and length
was scaled on the basis of 70 kg to the power of 0.75
(Eq. 6) [22, 23], while for the influence of WTexcess, a
separate function was estimated (Eq. 7). Figure 4 shows
the results of this excess weight model in which the final
covariate model for clearance in obese adolescents
(Table 2) was replaced by the excess weight covariate
model. This figure illustrates that using this approach
WTfor age and length scales allometrically to the power of
0.75 (Eq. 6), and that the influence of WTexcess was char-
acterised using Eq. 7, estimating a Y of 0.00698 (25%),
while the other parameter estimates were similar to the
final covariate model (Table 2). The excess weight
covariate model was as able as the final covariate model to
describe the data in terms of OFV (2488.0 vs. 2487.0;
p[ 0.05, Table 2) and goodness-of-fit plots.
4 Discussion
In this analysis, we report on the clearance of the CYP3A
substrate midazolam in obese adolescents and morbidly
obese adults. Throughout paediatric life, clearance is
known to increase for which allometric scaling with an
exponent of 0.75 is often used [19–21, 23]. Particularly for
adolescents, there is hardly any debate on the use of this
type of scaling [22]. In obesity, CYP3A activity seems to
be suppressed, which was not only supported by in-vitro
and obese mice studies [10–13], but also by the reported
increased CYP3A-mediated midazolam clearance after
substantial weight reduction upon bariatric surgery in
morbidly obese patients [15–17]. An important question is
how the CYP3A system is influenced by both age and
obesity, particularly in view of the increasing prevalence of
obesity in both adults and children.
This current study shows that obese adolescents have a
higher midazolam clearance compared with morbidly
obese adults. This finding is unexpected, because in general
adolescents are anticipated to have a lower clearance
compared with adults. However, the higher clearance in
obese adolescents may perhaps not be so unexpected when
recent studies on midazolam in morbidly obese patients
before and after bariatric surgery are taken into consider-
ation [14, 15]. In one study, morbidly obese adults showed
no change in clearance compared with non-obese adults
[14]. These results are explained by postulating that a
higher liver volume and/or liver blood flow will counteract
the previously reported lower CYP3A protein expression or
activity [10–13] caused by an increased inflammation state
[12, 25, 26, 33], ultimately resulting in a similar absolute
hepatic CYP3A-metabolizing capacity in both groups [14].
This hypothesis was supported by another study, in which
the pharmacokinetic study was repeated 1 year after bar-
iatric surgery in 18 of the 20 patients of the morbidly obese
study group, when they had on average lost 44.5 ± 10.2 kg
of body weight [15]. Using the exact same study design,
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the bariatric patients showed a 1.7 higher midazolam
clearance compared with the situation before surgery [15]
(Fig. 5). This increase was anticipated to result from the
recovery of obesity-suppressed hepatic CYP3A activity as
a consequence of the decreased inflammation status after
weight loss from bariatric surgery [15]. A semi-physio-
logically based pharmacokinetic model including the
1-OH-midazolam metabolite confirmed this finding, where
the intrinsic hepatic clearance of midazolam was 1.5 times
higher in bariatric patients compared with morbidly obese
patients before surgery [16]. As such, our finding of a
higher total midazolam plasma clearance in obese
adolescents compared with morbidly obese adults, can in
our opinion be explained by the hypothesis that the CYP3A
activity in obese adolescents is not (yet) suppressed to the
same extent as morbidly obese adults. Perhaps the duration
of (morbid) obesity and thereby the inflammatory status
that goes with obesity, is of influence on the final CYP3A
activity in the liver and can be considered the explanation
for our findings. Even though from the data this hypothesis
cannot be proven as no specific data on the duration of
obesity are available, this explanation seems more likely
than other differences between the groups such as differ-
ences in surgical procedure, anaesthetic regimen or BMI.
Table 2 Population pharmacokinetic parameters of the base and final pharmacokinetic model for midazolam in 19 obese adolescents and 20
morbidly obese adults and results of bootstrap analysis of the final model (927/1000 resamples successful)
Parameter Base model
(RSE%)
Excess weight
model (RSE%)
Final model
(RSE%)
Bootstrap (95%
confidence interval)
Fixed effects
CL (L/min) 0.58 (7)
CLobese adolescents = CL104.7 kg 9 (TBW/104.7)
W
CL104.7 kg 0.71 (7) 0.71 (0.59–0.78)
W 1.2 (31) 1.19 (1.08–1.99)
CLmorbidly obese adults (L/min) 0.44 (11) 0.44 (0.33–0.56)
CL(obese) adolescent = CLnon-obese adults
9 (WTfor age and length/70)
0.75 ? (Y 9 WTexcess)
CLnon-obese adults 0.45 (20)
Y 0.007 (25)
F 0.589 (12) 0.56 (14) 0.562 (12) 0.563 (0.45–0.74)
Ka = Ktr (min
-1) 0.114 (11) 0.114 (23) 0.115 (11) 0.115 (0.09–0.142)
Vcentral (L) 55.4 (11) 53.7 (12) 55.2 (11) 54.7 (42.2–66.8)
Vperipheral (L) 161 (12)
Vperipheral obese adolescents (L) 168 (15) 172 (13) 172.8 (132.9–235.1)
Vperipheral morbidly obese adults = V141.8 kg
9 (TBW/141.8)X
V141.8 kg 168 (15) 172 (13) 172.8 (132.9–235.1)
X 3.2 (58) 3.3 (33) 3.19 (1.08–5.33)
Q (L/min) 1.14 (12) 1.15 (11) 1.14 (12) 1.14 (0.91–1.47)
Inter-individual variability (%)
CL 39.9 (14) 22.6 (36) 21 (26) 17.8 (4.2–33.4)
F 42.9 (23) 39.2 (22) 39.2 (21) 38.2 (16.7–53.5)
Ka = Ktr 49.2 (17) 50.4 (12) 49.5 (17) 48.2 (34.9–61.0)
Vcentral 62 (11) 54.4 (22) 58.5 (11) 56.2 (28.1–83.0)
Vperipheral 41.9 (20) 39.6 (30) 42.2 (22) 37.1 (10.7–60.2)
Q 40.9 (17) 43.7 (22) 42.4 (25) 41.1 (18.7–56.7)
Residual variability (%)
Proportional error 29.6 (9) 29.9 (9) 29.7 (9) 29.6 (24.6–35.0)
OFV (-2LL) 2516.6 2488 2487.0 2463.2
CL clearance of midazolam, F oral bioavailability, Ka absorption rate constant, Ktr transit compartment rate constant, OFV objective function
value, Q inter-compartmental clearance of midazolam between the central and peripheral compartment, RSE relative standard error, TBW total
body weight, V volume of distribution
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This study also shows that the midazolam clearance in
obese adolescents seems even higher than in healthy non-
obese volunteers (Fig. 5) [14]. Based on this finding, it is
hypothesised that obese adolescents have, besides the (yet)
unaffected CYP3A activity, an increased liver size or
increased liver blood flow and/or perfusion like morbidly
obese adults [16, 34, 35]. This is further substantiated by
the result that within the obese adolescent population,
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midazolam clearance increases with TBW (Fig. 5), which
was mainly explained by excess body weight (WTexcess)
instead of developmental weight (WTfor age and length)
(Figs. 3, 4). Concerning the increase in liver blood flow
with body weight in obese adolescents, there is some evi-
dence from a study on propofol, which is a high extraction
ratio drug of which the clearance is mainly defined by liver
blood flow [36]. In this study, propofol clearance was
found to increase with body weight in (morbidly) obese
adolescents, indicating an increase in liver blood flow in
this population. This would point to a combination of an
increase in liver blood flow and unaffected CYP3A activity
being responsible for the elevated midazolam clearance in
obese adolescents.
When analysing pharmacokinetic data in obese ado-
lescents, it is important to be able to distinguish between
the influence of body weight resulting from development
or size and from obesity on the pharmacokinetic param-
eters [24]. Particularly because the prevalence of obesity
in children is increasing, which complicates scaling on the
basis of body weight. Previously, for busulfan, a model
was proposed evaluating the pharmacokinetics in under-,
normal and overweight children, adolescents and adults
[median age of 4 (0.1–35) years] [37]. The authors pro-
posed to divide the body weight of each patient into body
weight related to growth (body weight-for-age, BWfor age)
and body weight related to under/overweight (body
weight z score, BWz score) with separate functions for each
of these weights. This exploratory model showed that
both BWfor age and BWz score influenced busulfan clear-
ance, each in their own way [37]. For the analysis of
midazolam data in overweight and obese adolescents [27],
this model was adjusted into the (over)weight covariate
model, in which body weight for age and length
(WTfor age and length) was used instead of BWfor age
because the influence of length is more relevant for ado-
lescents. Another approach was reported by Diepstraten
et al. who performed a population pharmacokinetic meta-
analysis on propofol data from morbidly obese adults,
adolescents, children and their non-obese controls (body
weight 37–184 kg, age 9–79 years) [38]. In that report,
propofol clearance was found to increase with body
weight, while age was implemented as a second covariate
using a bilinear function [38]. As such, propofol clearance
values were found to increase with body weight but were
systematically lower in adolescents as compared with
adults, which is in contrast with the current results on the
CYP3A substrate midazolam for which higher values in
obese adolescents were found. The excess weight
covariate model we proposed here, may in our opinion
provide guidance on how to analyse data in obese ado-
lescents or children in future paediatric studies, as the
influence of weight from developmental growth and
obesity are separated and the influence of weight excess
can theoretically be positive or negative (Eq. 7). Such a
model is particularly of relevance because the prevalence
of obesity is not only increasing in adults but also in
children, thereby complicating the analysis of (often
scarce) paediatric data even further.
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Fig. 4 Midazolam clearance [population predicted (line) and empir-
ical Bayes estimates (triangles)] in obese adolescents vs. WTfor age
and length. Population clearance values of adolescents without over-
weight (WTexcess 0 kg, dotted line) is calculated by scaling the
clearance of adults on the basis of 70 kg to the power of 0.75 (Eq. 6)
[22]. Population clearance values of the obese adolescents (WTexcess
of 15, 45 and 90 kg, dark grey/black lines) are composed of the
clearance of adolescents without overweight (WTexcess 0 kg) supple-
mented by WTexcess of the obese adolescent times Z (Eq. 7). Observed
individual values of obese adolescents are represented by triangles
with colors varying according to the degree in WTexcess
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Fig. 5 Empirical Bayes estimates (EBEs) of midazolam clearance of
19 obese adolescents (black triangles) of the final pharmacokinetic
model vs. body weight. Values reported for 20 morbidly obese
patients (black dots) and 18 of the 20 morbidly obese patients 1 year
after bariatric surgery [15] (grey dots, with dotted lines for
corresponding values of these individuals at bariatric surgery) and
healthy volunteer studies (grey squares) [14, 47–53] are added for
comparison. Black lines are population mean estimates. Adapted from
Brill et al. [15] with permission
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It has been stated before that when dosing information is
not available in obese children, data can be extrapolated from
obese adults [39–41] provided practitioners consider the
effects of growth and development on the pharmacokinetics
relevant to the child’s age [40–42]. However, based on our
results, we conclude that data of morbidly obese adults cannot
be extrapolated to obese children as the duration of obesity is
probably of influence on the (patho)physiological changes
that are related to obesity. Using the excess weight covariate
model we propose here, TBW is divided into WTfor age and
length and WTexcess (TBW = WTfor age and length ? WTexcess).
Clearance for non-obese adolescents is calculated on the basis
of 70 kg to the power of 0.75 using clearance values in non-
obese adults (Eq. 6). While this approach is generally
accepted, particularly for adolescents [22], an advantage of
this approach is that data from non-obese adolescents are not
per se needed even though visual inspection may be useful as
we showed in Fig. 3a. Then, the influence of WTexcess on
clearance can be separately identified using visual inspection
(Fig. 3b, c) after which implementation of this covariate in
the model can be applied. Using this approach, both the
influence of size resulting from development/growth (i.e.
WTfor age and length) and size resulting from obesity (WTexcess)
can be separately studied and accounted for (Figs. 3, 4). It
seems that this function needs to be considered when clear-
ance is scaled to adolescents, as the percentage of obesity is
still increasing, especially in this age group.
One limiting factor of this study is that the obese ado-
lescents had a different ethnical background (5 Caucasians,
9 African Americans, 5 Hispanics) compared with the
morbidly obese adults (19 Caucasian, 1 African American).
Although race was not a significant covariate for clearance
in obese adolescents (DOFV -0.5; p[ 0.05), there was a
trend of a slightly higher clearance for the African Amer-
ican adolescents compared with the Caucasian or Hispanic
adolescents. In our opinion, this result is however more
likely explained by the fact that these African American
obese adolescents had a higher body weight. In addition,
multiple studies show that midazolam clearance is lower in
African Americans compared with Caucasians [43–45],
which suggests that our results could be even more extreme
if the adolescents with the highest body weight were
Caucasian. These ethnic differences are associated with
different frequencies of the CYP3A4*1B allele [44], but
these differences do not contribute substantially to the
inter-individual variability of CYP3A clearance [44, 46].
5 Conclusion
This study shows that midazolam clearance is higher in
obese adolescents compared with morbidly obese adults. A
possible explanation is that the CYP3A activity in obese
adolescents is not (yet) suppressed to the same extent as in
morbidly obese adults. As in obese adolescents WTexcess
was found to substantially influence clearance and their
clearance is also higher than that of non-obese adults, it
seems that this finding may be the result of an increased
liver size, liver blood flow and/or perfusion. From these
results it seems that obesity is a significant issue to consider
when scaling from adults to adolescents.
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